Endocrine-related cancer refers to cancer with endocrine function. This category mainly includes breast cancer, ovarian cancer, prostate cancer, multiple endocrine tumors, thyroid and parathyroid gland-related cancers, neuroendocrine-related tumors (neuroendocrine tumors, pituitary malignant tumors, paraganglioma), adrenal gland related malignant tumors (such as pheochromocytoma). In addition, bladder cancer, kidney cancer, lung cancer, and head and neck squamous cell carcinoma are also included.
Regulatory T cells (Tregs) are a class of immunoregulatory suppressor cells characterized by the expression of CD4, CD25 and Foxp3 (the transcription factor Forkhead box P3). It plays an important role in maintaining immune homeostasis and inducing immune tolerance, and its dysfunction directly leads to the imbalance of immune homeostasis. In the tumor microenvironment (TME), traditional T cells can be induced and differentiated into Tregs. Tregs have a strong immunosuppressive function, which can inhibit anti-tumor immunity and promote the occurrence and development of tumors. Tregs can also inhibit the function of immune effector cells through a variety of mechanisms, which is a key factor in tumor immune escape. However, the mechanism of Tregs' functional imbalance in tumor immune escape and immunotherapy still needs to be further explored. Unraveling the complex relationship between Tregs and the TME in the context of endocrine-related cancers is essential to advance cancer research and facilitate the development of effective therapeutic strategies.
This Research Topic aims to investigate the role and mechanism of regulatory T cells in regulating immune escape and immunotherapy in endocrine-related cancers. Our objectives are: (1) To uncover the mechanisms by which Tregs regulate the antitumor immunity of infiltrating T cells in the tumor microenvironment; (2) To reveal the role and mechanism of impaired Tregs in tumor immune escape; (3) To disclose the role and impact of Tregs in targeted immune checkpoint therapy; (4) To explore and screen novel therapeutic targets, novel regulatory mechanisms and targeted therapeutic drugs by analyzing the effect of Tregs in the immunotherapy of endocrine-related cancers; (5) To improve the prognosis of patients with endocrine-related cancers. These new findings can provide new strategies and ideas for the research of endocrine-related cancers, and promote the research of tumor immunotherapy to clinical application.
We invite researchers from different disciplines, including oncology, immunology, and metabolism, to contribute their original research articles, reviews, translational studies, and perspectives to this research topic. Submissions must focus on endocrine-related cancers and are encouraged to illustrate the latest advances and provide innovative perspectives in this rapidly evolving field.
Potential topics include, but are not limited to:
• Novel mechanism of abnormal function of endocrine-related cancers infiltrating Tregs on tumor immune escape and immunotherapy
• Regulation and mechanism of tumor-infiltrating immune cells and tumor cells on Tregs
• Novel immunotherapy strategies and targets for tumor-infiltrating Tregs
• Reprogramming mechanism of exTregs to eTregs and immunotherapy targeting Tregs reprogramming
• Tregs infiltration and its regulatory mechanisms in endocrine-related cancers: insights at single-cell resolution
• Novel mechanism of Tregs in immunotherapy resistance.
Keywords:
Regulatory T cells, Endocrine-Related Cancers, Immune Escape, Tumor microenvironment
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Endocrine-related cancer refers to cancer with endocrine function. This category mainly includes breast cancer, ovarian cancer, prostate cancer, multiple endocrine tumors, thyroid and parathyroid gland-related cancers, neuroendocrine-related tumors (neuroendocrine tumors, pituitary malignant tumors, paraganglioma), adrenal gland related malignant tumors (such as pheochromocytoma). In addition, bladder cancer, kidney cancer, lung cancer, and head and neck squamous cell carcinoma are also included.
Regulatory T cells (Tregs) are a class of immunoregulatory suppressor cells characterized by the expression of CD4, CD25 and Foxp3 (the transcription factor Forkhead box P3). It plays an important role in maintaining immune homeostasis and inducing immune tolerance, and its dysfunction directly leads to the imbalance of immune homeostasis. In the tumor microenvironment (TME), traditional T cells can be induced and differentiated into Tregs. Tregs have a strong immunosuppressive function, which can inhibit anti-tumor immunity and promote the occurrence and development of tumors. Tregs can also inhibit the function of immune effector cells through a variety of mechanisms, which is a key factor in tumor immune escape. However, the mechanism of Tregs' functional imbalance in tumor immune escape and immunotherapy still needs to be further explored. Unraveling the complex relationship between Tregs and the TME in the context of endocrine-related cancers is essential to advance cancer research and facilitate the development of effective therapeutic strategies.
This Research Topic aims to investigate the role and mechanism of regulatory T cells in regulating immune escape and immunotherapy in endocrine-related cancers. Our objectives are: (1) To uncover the mechanisms by which Tregs regulate the antitumor immunity of infiltrating T cells in the tumor microenvironment; (2) To reveal the role and mechanism of impaired Tregs in tumor immune escape; (3) To disclose the role and impact of Tregs in targeted immune checkpoint therapy; (4) To explore and screen novel therapeutic targets, novel regulatory mechanisms and targeted therapeutic drugs by analyzing the effect of Tregs in the immunotherapy of endocrine-related cancers; (5) To improve the prognosis of patients with endocrine-related cancers. These new findings can provide new strategies and ideas for the research of endocrine-related cancers, and promote the research of tumor immunotherapy to clinical application.
We invite researchers from different disciplines, including oncology, immunology, and metabolism, to contribute their original research articles, reviews, translational studies, and perspectives to this research topic. Submissions must focus on endocrine-related cancers and are encouraged to illustrate the latest advances and provide innovative perspectives in this rapidly evolving field.
Potential topics include, but are not limited to:
• Novel mechanism of abnormal function of endocrine-related cancers infiltrating Tregs on tumor immune escape and immunotherapy
• Regulation and mechanism of tumor-infiltrating immune cells and tumor cells on Tregs
• Novel immunotherapy strategies and targets for tumor-infiltrating Tregs
• Reprogramming mechanism of exTregs to eTregs and immunotherapy targeting Tregs reprogramming
• Tregs infiltration and its regulatory mechanisms in endocrine-related cancers: insights at single-cell resolution
• Novel mechanism of Tregs in immunotherapy resistance.
Keywords:
Regulatory T cells, Endocrine-Related Cancers, Immune Escape, Tumor microenvironment
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.